|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JPS6147500A
(ja)
|
1984-08-15 |
1986-03-07 |
Res Dev Corp Of Japan |
キメラモノクロ−ナル抗体及びその製造法
|
|
EP0173494A3
(en)
|
1984-08-27 |
1987-11-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric receptors by dna splicing and expression
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
US5731116A
(en)
|
1989-05-17 |
1998-03-24 |
Dai Nippon Printing Co., Ltd. |
Electrostatic information recording medium and electrostatic information recording and reproducing method
|
|
EP0768377A1
(en)
|
1988-09-02 |
1997-04-16 |
Protein Engineering Corporation |
Generation and selection of recombinant varied binding proteins
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
GB8905669D0
(en)
|
1989-03-13 |
1989-04-26 |
Celltech Ltd |
Modified antibodies
|
|
WO1991000906A1
(en)
|
1989-07-12 |
1991-01-24 |
Genetics Institute, Inc. |
Chimeric and transgenic animals capable of producing human antibodies
|
|
ES2284161T3
(es)
|
1990-01-12 |
2007-11-01 |
Amgen Fremont Inc. |
Generacion de anticuerpos xenogenicos.
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
CA2109602C
(en)
|
1990-07-10 |
2002-10-01 |
Gregory P. Winter |
Methods for producing members of specific binding pairs
|
|
AU8507191A
(en)
|
1990-08-29 |
1992-03-30 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
DE69133557D1
(de)
|
1990-08-29 |
2007-03-15 |
Pharming Intellectual Pty Bv |
Homologe rekombination in säugetier-zellen
|
|
ES2113940T3
(es)
|
1990-12-03 |
1998-05-16 |
Genentech Inc |
Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
|
|
DE69233769D1
(de)
|
1991-03-01 |
2009-09-24 |
Dyax Corp |
Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
|
|
AU662148B2
(en)
|
1991-04-10 |
1995-08-24 |
Scripps Research Institute, The |
Heterodimeric receptor libraries using phagemids
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
DE4122599C2
(de)
|
1991-07-08 |
1993-11-11 |
Deutsches Krebsforsch |
Phagemid zum Screenen von Antikörpern
|
|
PT1621554E
(pt)
|
1992-08-21 |
2009-07-13 |
Univ Bruxelles |
Imunoglobtainas desprovidas de cadeias leves
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
SE9600820D0
(sv)
|
1996-03-01 |
1996-03-01 |
Pharmacia Ab |
Antibodies and their use
|
|
JP3614866B2
(ja)
|
1997-06-12 |
2005-01-26 |
リサーチ コーポレイション テクノロジーズ，インコーポレイティド |
人工抗体ポリペプチド
|
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
|
US6727349B1
(en)
*
|
1998-07-23 |
2004-04-27 |
Millennium Pharmaceuticals, Inc. |
Recombinant anti-CCR2 antibodies and methods of use therefor
|
|
EP1137941B2
(en)
|
1998-12-10 |
2013-09-11 |
Bristol-Myers Squibb Company |
Protein scaffolds for antibody mimics and other binding proteins
|
|
US6818418B1
(en)
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
EP1163339A1
(en)
|
1999-04-01 |
2001-12-19 |
Innogenetics N.V. |
A polypeptide structure for use as a scaffold
|
|
DE60130538T2
(de)
|
2000-02-03 |
2008-06-12 |
Millenium Pharmaceuticals, Inc., Cambridge |
Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
|
|
EP1474161A4
(en)
|
2002-01-16 |
2005-06-29 |
Zyomyx Inc |
BINDING PROGRAMS MANUFACTURED BY ENGINEERING
|
|
WO2004056875A1
(en)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
|
US20070184052A1
(en)
|
2003-05-09 |
2007-08-09 |
Lin Herbert Y |
Soluble tgf-b type III receptor fusion proteins
|
|
CN1898267B
(zh)
|
2003-11-01 |
2012-05-23 |
默克专利股份有限公司 |
修饰的抗cd52抗体
|
|
US7501121B2
(en)
|
2004-06-17 |
2009-03-10 |
Wyeth |
IL-13 binding agents
|
|
PT1773885E
(pt)
|
2004-08-05 |
2010-07-21 |
Genentech Inc |
Antagonistas anti-cmet humanizados
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
CA2612241C
(en)
|
2005-07-01 |
2018-11-06 |
Medarex, Inc. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
|
|
RS56743B1
(sr)
|
2007-08-21 |
2018-03-30 |
Amgen Inc |
Humani c-fms antigen vezujući proteini
|
|
RU2531758C2
(ru)
|
2008-02-11 |
2014-10-27 |
Куретек Лтд. |
Моноклональные антитела для лечения опухолей
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
WO2010031168A1
(en)
|
2008-09-17 |
2010-03-25 |
National Research Council Of Canada |
HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
KR101772706B1
(ko)
|
2008-08-18 |
2017-08-29 |
화이자 인크. |
Ｃｃｒ２에 대한 항체
|
|
ES2545609T3
(es)
|
2008-08-25 |
2015-09-14 |
Amplimmune, Inc. |
Composiciones de antagonistas de PD-1 y métodos de uso
|
|
JP2012500652A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
標的化共刺激ポリペプチドおよび癌を処置するための使用方法
|
|
EP4209510B1
(en)
|
2008-12-09 |
2024-01-31 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
IT1395574B1
(it)
|
2009-09-14 |
2012-10-16 |
Guala Dispensing Spa |
Dispositivo di erogazione
|
|
GB0917044D0
(en)
|
2009-09-29 |
2009-11-18 |
Cytoguide As |
Agents, uses and methods
|
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
EP2949670B1
(en)
|
2009-12-10 |
2019-02-27 |
F. Hoffmann-La Roche AG |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
KR101656548B1
(ko)
|
2010-03-05 |
2016-09-09 |
에프. 호프만-라 로슈 아게 |
인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
|
|
PT2542590T
(pt)
|
2010-03-05 |
2017-08-31 |
Univ Johns Hopkins |
Composições e métodos para anticorpos e proteínas de fusão imunomoduladores direcionados
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
AR080698A1
(es)
|
2010-04-01 |
2012-05-02 |
Imclone Llc |
Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
|
|
SMT201900074T1
(it)
|
2010-05-04 |
2019-02-28 |
Five Prime Therapeutics Inc |
Anticorpi che legano csf1r
|
|
WO2011155607A1
(ja)
|
2010-06-11 |
2011-12-15 |
協和発酵キリン株式会社 |
抗ｔｉｍ－３抗体
|
|
US9624298B2
(en)
|
2011-11-28 |
2017-04-18 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
|
EP2791174B1
(en)
|
2011-12-15 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r and uses thereof
|
|
KR20150018533A
(ko)
|
2012-05-11 |
2015-02-23 |
파이브 프라임 테라퓨틱스, 인크. |
콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
|
|
WO2013192596A2
(en)
|
2012-06-22 |
2013-12-27 |
Sorrento Therapeutics Inc. |
Antigen binding proteins that bind ccr2
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
CN104684582A
(zh)
|
2012-08-31 |
2015-06-03 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
US9522196B2
(en)
|
2012-12-25 |
2016-12-20 |
Kagoshima University |
Antibody recognizing folate receptors α and β
|
|
EP2986642A1
(en)
|
2013-04-17 |
2016-02-24 |
MorphoSys AG |
Antibodies targeting specifically human cxcr2
|
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
|
AU2014308751B2
(en)
|
2013-08-22 |
2020-03-05 |
Acceleron Pharma, Inc. |
TGF-beta receptor type II variants and uses thereof
|
|
EP3105246B1
(en)
|
2014-02-10 |
2021-03-31 |
Merck Patent GmbH |
Targeted tgf beta inhibition
|
|
EA201791421A1
(ru)
|
2014-12-22 |
2017-10-31 |
Файв Прайм Терапьютикс, Инк. |
Антитела против csf1r для лечения pvns
|
|
BR112017020952A2
(pt)
*
|
2015-04-13 |
2018-07-10 |
Five Prime Therapeutics Inc |
método de tratamento de câncer, composição e uso da composição
|
|
EP3302558A4
(en)
|
2015-06-01 |
2019-01-16 |
The Rockefeller University |
ANTI-TUMOR MEDIUM AND METHOD OF USE
|
|
RU2018102575A
(ru)
|
2015-06-24 |
2019-07-25 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против человеческого csf-1r, предназначенные для применения для индукции лимфоцитоза при лимфомах или лейкозах
|
|
CA2996996A1
(en)
|
2015-08-31 |
2017-03-09 |
National Research Council Of Canada |
Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
|
|
JP7082604B2
(ja)
|
2016-03-21 |
2022-06-08 |
マレンゴ・セラピューティクス，インコーポレーテッド |
多重特異性および多機能性分子ならびにその使用
|
|
JP2020517256A
(ja)
*
|
2017-04-19 |
2020-06-18 |
エルスター セラピューティクス， インコーポレイテッド |
多重特異性分子およびその使用
|
|
EP3720881A1
(en)
*
|
2017-12-08 |
2020-10-14 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|